Morgan Stanley Lowers Compass Pathways Stock Price Target Amid TRD Progress

Morgan Stanley has reduced its stock price target for Compass Pathways to $X from $Y, citing progress in development for treatments related to TRD (treatment-resistant depression). The update reflects changing expectations related to the company's clinical trials and market potential. This adjustment may impact investor sentiment and trading volumes for Compass Pathways shares.